Vabysmo Is Bright Spot For Roche In Bumpy Q3
Anticipation Grows On Alzheimer’s Result
Executive Summary
Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.
You may also be interested in...
Roche Eyes Adjuvant HCC Setting After Phase III Tecentriq Combination Success
The firm’s Tecentriq has bounced back from recent setbacks with a pivotal success in the adjuvant liver cancer setting.
Roche Withdraws Tecentriq’s Frontline Bladder Cancer Indication, Ceding Market To Keytruda
The move marks the second time since last year that Roche has withdrawn a urothelial carcinoma indication after its confirmatory trial failed to show an overall survival benefit.
Roche’s Vabysmo Chases Regeneron’s Eylea With New Pivotal Macular Edema Wins
The Swiss major’s new bispecific antibody could challenge Eylea’s standard of care status in another ophthalmic indication, macular edema due to retinal vein occlusion, but the older rival is set to hit back in bigger markets with a high-dose reformulation.